Home » LifeCycle Pharma Submits Phase III Protocol for LCP-Tacro to FDA
LifeCycle Pharma Submits Phase III Protocol for LCP-Tacro to FDA
LifeCycle Pharma A/S announced that LCP has submitted the phase 3 protocol for LCP-Tacro in de novo kidney transplant recipients to the Food and Drug Administration in [the] United States.
StreetInsider
StreetInsider
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May